Incyte Corporation (INCY) Earnings Yield: 7.21%
Is Incyte Corporation’s earnings yield high or low?
Incyte Corporation's earnings yield of 7.21% is 99% above its 5-year average of 3.62%, near the high end of its 5-year range (0.17%–7.67%).
As of Sunday, June 21, 2026. 18.52% above its 12-month average of 6.08%.
INCY Earnings Yield Chart
INCY Average Earnings Yield Chart
INCY Current vs Average Earnings Yield Chart
INCY Earnings Yield Metrics
EARNINGS YIELD
7.21%
EARNINGS YIELD AVG TTM
6.08%
EARNINGS YIELD AVG 3Y
3.35%
EARNINGS YIELD AVG 5Y
3.62%
EARNINGS YIELD AVG 10Y
2.91%
EARNINGS YIELD AVG 15Y
N/A
EARNINGS YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
+18.52%
CURRENT VS 3Y AVG
+114.92%
CURRENT VS 5Y AVG
+98.93%
CURRENT VS 10Y AVG
+147.51%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
INCY Competitors' Earnings Yield
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incyte Corporation (INCY) | $19.62B | 7.21% | 6.08% | 3.35% | 3.62% |
| Labcorp Holdings Inc. (LH)vs › | $20.98B | 4.41% | 3.73% | 3.33% | 6.03% |
| Viatris Inc. (VTRS)vs › | $17.90B | N/A | 12.06% | 8.72% | 5.27% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.02B | 4.38% | 4.29% | 3.81% | 2.97% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 3.16% | 3.63% | 3.48% | 5.61% |
| United Therapeutics Corporation (UTHR)vs › | $22.78B | 5.04% | 6.04% | 6.91% | 6.45% |
| BioNTech SE (BNTX)vs › | $22.98B | N/A | 8.30% | 19.01% | 16.60% |
| Mettler-Toledo International Inc. (MTD)vs › | $23.13B | 3.73% | 3.16% | 3.11% | 2.84% |
| Waters Corporation (WAT)vs › | $23.17B | 2.21% | 3.19% | 3.30% | 3.36% |
| Veeva Systems Inc. (VEEV)vs › | $24.90B | 3.66% | 2.33% | 1.93% | 1.66% |
Earnings Yield vs P/E Ratio
Earnings Yield
7.21%
EPS ÷ Price
P/E Ratio
13.9
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
- It expresses earnings relative to share price as a percentage
- It can be compared with FCF yield and dividend yield
- It can be compared with bond yields because both are percentages
- It is mathematically the inverse of the P/E ratio
Incyte Corporation Earnings Yield Formula & Definition
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Incyte Corporation Earnings Yield FAQ
- What is the earnings yield for Incyte Corporation (INCY)?
- The earnings yield for INCY stock is 7.21%.
- Is Incyte Corporation's earnings yield high or low?
- Incyte Corporation's earnings yield of 7.21% is 99% above its 5-year average of 3.62%, near the high end of its 5-year range (0.17%–7.67%).
- What is the TTM average earnings yield for Incyte Corporation (INCY)?
- The TTM average earnings yield for INCY stock is 6.08%.
- What is the 3Y average earnings yield for Incyte Corporation (INCY)?
- The 3Y average earnings yield for INCY stock is 3.35%.
- What is the 5Y average earnings yield for Incyte Corporation (INCY)?
- The 5Y average earnings yield for INCY stock is 3.62%.
- What is the 10Y average earnings yield for Incyte Corporation (INCY)?
- The 10Y average earnings yield for INCY stock is 2.91%.
Incyte Corporation Earnings Yield History
| DATE | EARNINGS YIELD |
|---|---|
| 2026-06-18 | 7.21% |
| 2026-06-17 | 7.15% |
| 2026-06-16 | 7.10% |
| 2026-06-15 | 6.94% |
| 2026-06-12 | 6.52% |
| 2026-06-11 | 6.57% |
| 2026-06-10 | 6.72% |
| 2026-06-09 | 6.86% |
| 2026-06-08 | 7.04% |
| 2026-06-05 | 6.92% |
| 2026-06-04 | 6.99% |
| 2026-06-03 | 7.23% |
| 2026-06-02 | 7.67% |
| 2026-06-01 | 7.41% |
| 2026-05-29 | 7.32% |
| 2026-05-28 | 7.26% |
| 2026-05-27 | 7.27% |
| 2026-05-26 | 7.29% |
| 2026-05-22 | 7.29% |
| 2026-05-21 | 7.27% |
| 2026-05-20 | 7.29% |
| 2026-05-19 | 7.41% |
| 2026-05-18 | 7.44% |
| 2026-05-15 | 7.43% |
| 2026-05-14 | 7.25% |
| 2026-05-13 | 7.16% |
| 2026-05-12 | 7.14% |
| 2026-05-11 | 7.06% |
| 2026-05-08 | 7.18% |
| 2026-05-07 | 7.24% |
| 2026-05-06 | 7.09% |
| 2026-05-05 | 7.26% |
| 2026-05-04 | 7.29% |
| 2026-05-01 | 7.30% |
| 2026-04-30 | 7.43% |
| 2026-04-29 | 7.14% |
| 2026-04-28 | 7.24% |
| 2026-04-27 | 6.70% |
| 2026-04-24 | 6.77% |
| 2026-04-23 | 6.72% |
| 2026-04-22 | 6.63% |
| 2026-04-21 | 6.66% |
| 2026-04-20 | 6.61% |
| 2026-04-17 | 6.55% |
| 2026-04-16 | 6.72% |
| 2026-04-15 | 6.60% |
| 2026-04-14 | 6.56% |
| 2026-04-13 | 6.71% |
| 2026-04-10 | 6.67% |
| 2026-04-09 | 6.61% |
| 2026-04-08 | 6.68% |
| 2026-04-07 | 6.84% |
| 2026-04-06 | 6.76% |
| 2026-04-02 | 6.68% |
| 2026-04-01 | 6.80% |
| 2026-03-31 | 6.81% |
| 2026-03-30 | 7.10% |
| 2026-03-27 | 7.10% |
| 2026-03-26 | 6.95% |
| 2026-03-25 | 6.95% |
| 2026-03-24 | 7.07% |
| 2026-03-23 | 7.09% |
| 2026-03-20 | 7.06% |
| 2026-03-19 | 6.90% |
| 2026-03-18 | 6.95% |
| 2026-03-17 | 6.80% |
| 2026-03-16 | 6.89% |
| 2026-03-13 | 6.93% |
| 2026-03-12 | 6.96% |
| 2026-03-11 | 6.77% |
| 2026-03-10 | 6.68% |
| 2026-03-09 | 6.60% |
| 2026-03-06 | 6.68% |
| 2026-03-05 | 6.59% |
| 2026-03-04 | 6.49% |
| 2026-03-03 | 6.54% |
| 2026-03-02 | 6.41% |
| 2026-02-27 | 6.33% |
| 2026-02-26 | 6.41% |
| 2026-02-25 | 6.41% |
| 2026-02-24 | 6.35% |
| 2026-02-23 | 6.36% |
| 2026-02-20 | 6.33% |
| 2026-02-19 | 6.30% |
| 2026-02-18 | 6.22% |
| 2026-02-17 | 6.34% |
| 2026-02-13 | 6.34% |
| 2026-02-12 | 6.36% |
| 2026-02-11 | 6.49% |
| 2026-02-10 | 6.41% |
| 2026-02-09 | 5.48% |
| 2026-02-06 | 5.51% |
| 2026-02-05 | 5.81% |
| 2026-02-04 | 5.82% |
| 2026-02-03 | 5.92% |
| 2026-02-02 | 5.81% |
| 2026-01-30 | 5.97% |
| 2026-01-29 | 5.91% |
| 2026-01-28 | 5.90% |
| 2026-01-27 | 5.77% |
| 2026-01-26 | 5.82% |
| 2026-01-23 | 5.85% |
| 2026-01-22 | 5.68% |
| 2026-01-21 | 5.70% |
| 2026-01-20 | 5.82% |
| 2026-01-16 | 5.62% |
| 2026-01-15 | 5.67% |
| 2026-01-14 | 5.63% |
| 2026-01-13 | 5.77% |
| 2026-01-12 | 5.61% |
| 2026-01-09 | 5.59% |
| 2026-01-08 | 5.64% |
| 2026-01-07 | 5.40% |
| 2026-01-06 | 5.60% |
| 2026-01-05 | 5.87% |
| 2026-01-02 | 5.89% |
| 2025-12-31 | 6.05% |
| 2025-12-30 | 6.04% |
| 2025-12-29 | 6.01% |
| 2025-12-26 | 5.96% |
| 2025-12-24 | 5.95% |
| 2025-12-23 | 5.92% |
| 2025-12-22 | 5.93% |
| 2025-12-19 | 5.81% |
| 2025-12-18 | 6.13% |
| 2025-12-17 | 6.12% |
| 2025-12-16 | 6.15% |
| 2025-12-15 | 6.05% |
| 2025-12-12 | 6.26% |
| 2025-12-11 | 6.21% |
| 2025-12-10 | 6.27% |
| 2025-12-09 | 6.27% |
| 2025-12-08 | 6.17% |
| 2025-12-05 | 5.82% |
| 2025-12-04 | 5.94% |
| 2025-12-03 | 5.88% |
| 2025-12-02 | 5.89% |
| 2025-12-01 | 5.85% |
| 2025-11-28 | 5.71% |
| 2025-11-26 | 5.65% |
| 2025-11-25 | 5.66% |
| 2025-11-24 | 5.62% |
| 2025-11-21 | 5.85% |
| 2025-11-20 | 5.87% |
| 2025-11-19 | 5.89% |
| 2025-11-18 | 5.75% |
| 2025-11-17 | 5.73% |
| 2025-11-14 | 5.73% |
| 2025-11-13 | 5.66% |
| 2025-11-12 | 5.52% |
| 2025-11-11 | 5.52% |
| 2025-11-10 | 5.63% |
| 2025-11-07 | 5.63% |
| 2025-11-06 | 5.68% |
| 2025-11-05 | 5.65% |
| 2025-11-04 | 5.80% |
| 2025-11-03 | 5.88% |
| 2025-10-31 | 6.39% |
| 2025-10-30 | 6.45% |
| 2025-10-29 | 6.62% |
| 2025-10-28 | 6.51% |
| 2025-10-27 | 4.73% |
| 2025-10-24 | 4.82% |
| 2025-10-23 | 4.93% |
| 2025-10-22 | 5.00% |
| 2025-10-21 | 5.04% |
| 2025-10-20 | 5.11% |
| 2025-10-17 | 5.03% |
| 2025-10-16 | 5.04% |
| 2025-10-15 | 4.99% |
| 2025-10-14 | 5.12% |
| 2025-10-13 | 5.19% |
| 2025-10-10 | 5.25% |
| 2025-10-09 | 5.19% |
| 2025-10-08 | 5.15% |
| 2025-10-07 | 5.05% |
| 2025-10-06 | 5.04% |
| 2025-10-03 | 5.07% |
| 2025-10-02 | 5.10% |
| 2025-10-01 | 5.08% |
| 2025-09-30 | 5.19% |
| 2025-09-29 | 5.24% |
| 2025-09-26 | 5.32% |
| 2025-09-25 | 5.39% |
| 2025-09-24 | 5.23% |
| 2025-09-23 | 5.21% |
| 2025-09-22 | 5.19% |
| 2025-09-19 | 5.08% |
| 2025-09-18 | 5.12% |
| 2025-09-17 | 5.19% |
| 2025-09-16 | 5.24% |
| 2025-09-15 | 5.29% |
| 2025-09-12 | 5.29% |
| 2025-09-11 | 5.11% |
| 2025-09-10 | 5.10% |
| 2025-09-09 | 5.14% |
| 2025-09-08 | 5.08% |
| 2025-09-05 | 5.08% |
| 2025-09-04 | 5.15% |
| 2025-09-03 | 5.06% |
| 2025-09-02 | 5.12% |
| 2025-08-29 | 5.20% |
| 2025-08-28 | 5.26% |
| 2025-08-27 | 5.19% |
| 2025-08-26 | 5.24% |
| 2025-08-25 | 5.19% |
| 2025-08-22 | 5.17% |
| 2025-08-21 | 5.08% |
| 2025-08-20 | 5.10% |
| 2025-08-19 | 5.15% |
| 2025-08-18 | 5.18% |
| 2025-08-15 | 5.06% |
| 2025-08-14 | 5.11% |
| 2025-08-13 | 5.13% |
| 2025-08-12 | 5.39% |
| 2025-08-11 | 5.56% |
| 2025-08-08 | 5.61% |
| 2025-08-07 | 5.63% |
| 2025-08-06 | 5.67% |
| 2025-08-05 | 5.66% |
| 2025-08-04 | 5.64% |
| 2025-08-01 | 5.82% |
| 2025-07-31 | 5.88% |
| 2025-07-30 | 5.68% |
| 2025-07-29 | 5.69% |
| 2025-07-28 | 0.46% |
| 2025-07-25 | 0.46% |
| 2025-07-24 | 0.45% |
| 2025-07-23 | 0.45% |
| 2025-07-22 | 0.46% |
| 2025-07-21 | 0.47% |
| 2025-07-18 | 0.47% |
| 2025-07-17 | 0.46% |
| 2025-07-16 | 0.46% |
| 2025-07-15 | 0.47% |
| 2025-07-14 | 0.46% |
| 2025-07-11 | 0.47% |
| 2025-07-10 | 0.45% |
| 2025-07-09 | 0.47% |
| 2025-07-08 | 0.47% |
| 2025-07-07 | 0.48% |
| 2025-07-03 | 0.47% |
| 2025-07-02 | 0.47% |
| 2025-07-01 | 0.47% |
| 2025-06-30 | 0.47% |
| 2025-06-27 | 0.47% |
| 2025-06-26 | 0.45% |
| 2025-06-25 | 0.47% |
| 2025-06-24 | 0.46% |
| 2025-06-23 | 0.48% |
| 2025-06-20 | 0.47% |
| 2025-06-18 | 0.47% |
| 2025-06-17 | 0.47% |
| 2025-06-16 | 0.45% |
| 2025-06-13 | 0.47% |
| 2025-06-12 | 0.46% |
| 2025-06-11 | 0.46% |
| 2025-06-10 | 0.46% |
| 2025-06-09 | 0.46% |
| 2025-06-06 | 0.47% |
Showing the most recent 260 of 1,967 data points. The chart above shows the full history.
Related Metrics
About Incyte Corporation
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- William J. Meury